NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
93.89
+3.66 (+4.06%)
As of 10:57AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close90.23
Open94.82
Bid93.95 x 800
Ask93.96 x 900
Day's Range93.67 - 95.00
52 Week Range72.27 - 95.00
Volume3,243,016
Avg. Volume2,227,687
Market Cap216.664B
Beta (3Y Monthly)0.55
PE Ratio (TTM)17.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.83 (3.14%)
Ex-Dividend Date2019-03-04
1y Target EstN/A
Trade prices are not sourced from all markets
  • Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
    Zacks59 minutes ago

    Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

    Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

  • Stocks Stumble As Netflix Dives; Dow Jones Stock IBM Breaks Out, Apple Upgraded
    Investor's Business Daily1 hour ago

    Stocks Stumble As Netflix Dives; Dow Jones Stock IBM Breaks Out, Apple Upgraded

    Novartis and eBay grabbed early leads Thursday as Netflix slammed the Nasdaq, even as an analyst upgrade lifted Dow Jones stock Apple toward a buy point.

  • Novartis Earnings Top; Swiss Drug Giant Soars
    Investor's Business Daily2 hours ago

    Novartis Earnings Top; Swiss Drug Giant Soars

    Novartis earnings topped views, while Q2 revenue was in line. The Swiss drug giant raised some 2019 guidance. Shares leapt toward a record high.

  • Novartis raises full-year targets, aims to settle U.S. lawsuit
    Reuters5 hours ago

    Novartis raises full-year targets, aims to settle U.S. lawsuit

    Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors. Shares in the company rose about 5% to their highest since 2015, buoyed by second-quarter results, earnings guidance and the prospect of avoiding trial in a case that began in 2011 as a whistleblower lawsuit filed by a former employee. The lawsuit, since joined by the U.S. government, contends that Novartis paid millions of dollars in kickbacks to doctors so they would prescribe its products, including hypertension treatment Lotrel and diabetes drug Starlix.

  • Novartis’s Brightened Outlook Pushes Shares to All-Time High
    Bloomberg6 hours ago

    Novartis’s Brightened Outlook Pushes Shares to All-Time High

    (Bloomberg) -- Novartis AG raised its earnings outlook for the second time this year, driving the shares to an all-time high, and said the launch of its $2.1 million gene therapy is on track despite concerns over coverage barriers.Earnings excluding some items are expected to increase by a low double-digit to mid-teens percentage this year, the Basel, Switzerland-based company said. Novartis previously forecast a high single-digit percentage increase. The stock climbed as much as 3.4% in Zurich.The Swiss drugmaker also boosted its outlook for sales, new medicines and the Sandoz generics unit as Chief Executive Officer Vas Narasimhan work to reshape the company’s strategy begins to pay off. Narasimhan has spun off the Alcon eye-care division, ditched a stake in a consumer-health venture and unveiled a series of acquisitions after taking the helm early last year.Novartis at the same time has sought to sharpen its focus on cutting-edge drugs for cancer and rare illnesses, rolling out products like gene therapy Zolgensma aimed at a devastating muscle disease. Approved in the U.S. in May, the treatment has experienced “strong uptake,” Narasimhan told reporters.While analysts have flagged restrictions with U.S. health-care providers, the CEO said on a call that the launch is progressing in line with expectations. Novartis has contracts with insurers covering about 40% of patients with commercial health plans, Narasimhan said. The company said in May it expected to have 30% coverage in the first month after approval. He added that four state Medicaid plans have Zolgensma coverage in place.Nearly all patients who have sought the therapy and are eligible based on the drug’s label “have achieved an approval to be treated with the medicine after the appropriate steps are taken,” he said. “We’re continuing to advance our efforts, both getting medical policies in place and contracts in place with key payers.”Novartis shares have climbed about 24% this year, doubling the gain in the Bloomberg index that tracks European pharma companies.Novartis also has set aside about $700 million for a potential settlement in a U.S. case involving allegations it paid kickbacks to doctors who prescribed its drugs. A letter made public last month said the parties had made “significant progress” on reaching a deal.Psoriasis treatment Cosentyx, poised to become the company’s top seller this year after a 25% sales boost last quarter, is also in focus amid rising competition in the immunology field.Novartis already raised its profit forecast in April, saying it expected earnings excluding some items to increase by a high single-digit percentage. At the time it left its sales outlook unchanged. Sales are now expected to grow by a mid to high-single digit percentage.To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John LauermanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Investing.com8 hours ago

    StockBeat: A Sea of Red as Earnings Live Down to Expectations

    By Geoffrey Smith

  • The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
    Motley Fool20 hours ago

    The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On

    Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.

  • Why Earnings Season Could Be Great for Novartis (NVS)
    Zacksyesterday

    Why Earnings Season Could Be Great for Novartis (NVS)

    Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
    Zacksyesterday

    Merck's Antibiotic Recarbrio Gets FDA Nod for Infections

    The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.

  • Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
    Zacksyesterday

    Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel

    Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.

  • Zacksyesterday

    Trade Talk Cools Off Record-Setting Market

    Trade Talk Cools Off Record-Setting Market

  • Should You Pick Up Novartis (NVS) Before Q2 Earnings?
    Zacks2 days ago

    Should You Pick Up Novartis (NVS) Before Q2 Earnings?

    Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.

  • Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
    Zacks2 days ago

    Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

    Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

  • Eisai boosts focus on Alzheimer's with new research facility, funding
    American City Business Journals2 days ago

    Eisai boosts focus on Alzheimer's with new research facility, funding

    Japanese drugmaker Eisai is investing $120 million over three years in an Alzheimer's research center — a 20 percent increase over the funding Eisai originally had allocated for the facility.

  • Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
    Zacks2 days ago

    Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA

    The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.

  • Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
    Zacks2 days ago

    Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

    Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

  • J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
    Zacks3 days ago

    J&J Falls Amid Reports of Criminal Probe Into Talcum Powder

    The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.

  • Financial Times4 days ago

    GSK to appoint Jonathan Symonds as chairman

    GlaxoSmithKline is to hire Jonathan Symonds, a former finance director at rival drugmakers AstraZeneca and Novartis, as its new chairman to oversee a break-up of the UK pharmaceuticals group. The appointment of Mr Symonds, who is currently deputy group chairman of HSBC, will end a six-month search for a replacement for Sir Philip Hampton, who has been non-executive chairman of GSK since 2015. Mr Symonds has extensive experience of the pharmaceutical industry.

  • Motley Fool6 days ago

    What Happened in the Stock Market Today

    On a record day for the major benchmarks, Illumina issued a warning, and Novartis and Amgen reported the failure of an Alzheimer's drug.

  • Amgen & Novartis' Alzheimer Studies End in Another Failure
    Zacks6 days ago

    Amgen & Novartis' Alzheimer Studies End in Another Failure

    Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

  • Benzinga6 days ago

    Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

    A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ )'s Janssen unit;  Merck & Co., Inc. (NYSE: ...

  • Aimmune Down on Negative ICER Review on Allergy Candidate
    Zacks6 days ago

    Aimmune Down on Negative ICER Review on Allergy Candidate

    Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

  • Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails
    Investor's Business Daily6 days ago

    Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails

    Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...